These results demonstrate proof-of-concept for the direct therapeutic correction of the most common CF-causing CFTR mutation and serve as a roadmap for engineering PE strategies at difficult-to-edit therapeutic targets. This evidence concerns the gene CFTR and cystic fibrosis.